Bioscience News - GEG Tech top picks

Researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster have developed the first widely protective vaccine against chlamydia, a common STI that is mostly asymptomatic but impacts 113 million people around the world each year and can result in infertility.

In a study, recently published in the journal Vaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.

Thanks to Labiotech!

Teaser:

"GEG-Tech is specialized in customized design and production of lentiviral vectors, and last November Labiotech helped to get more visitors onto their website. The campaign was a great success, leading this company to an increase in sales and to close a deal with a Big Pharma."